Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00854724 · ClinicalTrials.gov registry record · Phase 2

Puerarin Effects on Alcohol Drinking

A Phase 2 study, sponsored by Mclean Hospital.

Completed
Registry status
Phase 2
Development phase
16
Enrollment target

NCT00854724 is a Phase 2 study that has completed, run by Mclean Hospital. The registered enrollment target is 16 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00854724, a Phase 2 study, has completed, sponsored by Mclean Hospital.

COMPLETED
Registry status
Phase 2
Development phase
16 participants
Enrollment target

Study Summary

This research is designed to assess the impact of pretreatment with puerarin (NPI-031G), a major ingredient in the plant kudzu, on alcohol drinking. Hypothesis: Short-term treatment with this compound will reduce alcohol self-administration in a simulated natural settings laboratory.

Interventions

  • DRUG Puerarin, Placebo

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2009-02
Est. Completion 2011-07
Phase Phase 2

Sponsor

Mclean Hospital

140 total trials

What the Registry Record Tells You About NCT00854724

The ClinicalTrials.gov registry entry for NCT00854724 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Puerarin, Placebo is the first listed.

NCT00854724 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00854724 about?

NCT00854724 is a clinical study titled "Puerarin Effects on Alcohol Drinking". This research is designed to assess the impact of pretreatment with puerarin (NPI-031G), a major ingredient in the plant kudzu, on alcohol drinking. Hypothesis: Short-term treatment with this compound will reduce alcohol self-administration in a simulated natural settings laboratory.

What is the current status of trial NCT00854724?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2009-02. Estimated completion is 2011-07.

What interventions are being tested in trial NCT00854724?

The interventions under investigation include: Puerarin, Placebo (DRUG).

Who is sponsoring clinical trial NCT00854724?

This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.